Hao Zeng

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion”.

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion

Molecular Cancer Research(2024)10.1158/1541-7786.mcr-23-1003

N/A

0.282DataRank · unranked

5 citations

Karlie N. Lucas, Sateja Paradkar, Joseph Edmonds, Sam Friedman, Matthew A. Murray +12 more

1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1714

N/A

0DataRank · unranked

0 citations

D. Ye, Hanxu Guo, Yuchong Yang, Bing Xue, Xiao Zhang +15 more